Unfortunately for foreign devicemakers, import substitution appears to be one of the means by which China intends to achieve its goal of creating 10 med tech breadwinners worth 5 billion yuan ($820 million) apiece by 2020.
Sanofi, which bought controlling interest in Dubai's Globalpharma in June, will kick off production there with generics of 6 of its drugs. Sanofi is now managing the facility.
Eli Lilly has published a how-to paper about its ambitious technology transfer program to help China, India, Russia and South Africa produce two drugs to treat multidrug-resistant tuberculosis. The bottom line is that the undertaking was harder than expected, and while it did not fully achieve all of its goals, it was worth doing.
Multinational pharma companies have been targeting China for years with an eye on its aging population, expanding middle class and growing incidence of chronic maladies like diabetes. So how are Germany's leading pharmas, Bayer and Merck KGaA, carving out an edge for themselves? Reputation, tech-sharing and cold, hard cash.
WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.
DKSH, a well-heeled pharma marketing operation, has reupped with Roche, expanding a long-standing agreement to include more of Asia.
Tuesday, two women pleaded guilty in a Polish court to handing a health fund official a trip worth more than $1,000 in exchange for backing the sale of a certain drug. And one of those women was a Novartis employee, the company said Thursday.
Now, it's Sanofi digging into potential bribery in the Middle East. The French drugmaker told U.S. officials that it's eyeing allegations from an anonymous whistleblower about improper payments from 2007 to 2012.
In a diversification bid, Charlotte, NC-based Carlisle Companies purchased Singapore's LHi Technology, a device industry supplier focused on cable manufacturing, for $195 million.
Indian CRO GVK Biosciences is working to get back in the good graces of European regulators after inspectors found evidence that its employees doctored clinical trial results.